When pediatric patients with moderate-to-severe psoriasis require systemic treatment, a structured first-line nonbiologic approach applies — covering plaque psoriasis, extensive guttate disease, and other subtypes that go beyond topical management.
Children and adolescents with moderate-to-severe plaque psoriasis or extensive guttate psoriasis who are candidates for systemic therapy. Agent selection is guided by psoriasis subtype, patient age, and individual clinical factors.
The protocol uses nonbiologic systemic therapy. Multiple oral agents are included — among them a well-studied immunosuppressive option and a nonimmunosuppressive alternative — with the choice depending on the specific presentation and patient profile. The full selection criteria, sequencing, and monitoring guidance are in the protocol.
The target is measurable improvement in psoriasis. Response timelines differ by agent, with improvement typically observed within weeks of initiation; the full effect may take longer to reach. The protocol specifies expected response windows for each option.
DOI: 10.1016/j.jaad.2019.08.049